Actelion Ltd. Sale Possible If New Drug Fails

Published: Jun 13, 2011

Actelion (ATLN.VX) could consider putting itself up for sale if key drug macitentan fails, an executive was quoted as saying on Sunday after the firm rebuffed the same demand from activist investor Elliott. "Should macitentan not be successful then all strategic options are possible, up to and including a sale," Roland Haefeli, Actelion head of investor relations, told Der Sonntag newspaper.

Back to news